Incb099280

4 trials

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

4 Completed trials

1 Sponsors

12 Countries

Phase II

Phase I/II

Phase I (Other)

Phase II: 2 Phase I/II: 1 Phase I (Other): 1

Indications tested

Metastatic malignant melanoma 2 Non-small cell lung cancer stage IV 2 Malignant melanoma stage IV 2 Malignant melanoma 2 Non-small cell lung cancer metastatic 2 Non-small cell lung cancer 2 Non-small cell lung cancer stage III 1 Renal cancer stage IV 1 Colorectal adenocarcinoma 1 Non-small cell lung cancer recurrent 1 Non-small cell lung cancer stage IIIB 1 Skin squamous cell carcinoma recurrent 1

Sponsors using this IMP

All trials

4 total

A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended

2023-503223-26-00 Phase I/II 3 countries Incyte Corp.
A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended

2022-502716-37-00 Phase II 3 countries Incyte Corp.
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended

2022-502476-23-00 Phase II 7 countries Incyte Corp.
A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors Ended

2023-503243-34-00 Phase I (Other) 3 countries Incyte Corp.

Showing 1–4 of 4 trials

← All drugs A–Z